Given their superior or comparable efficacy in reducing HbA1c, coupled with additional benefits such as weight loss and a low risk of hypoglycemia, GLP-1 RAs are increasingly recommended as the preferred first-line injectable therapy for T2DM, often even before insulin. This evidence concerns the gene GLP1R and Hypoglycemia.